Cited by 618Cardiac Ischemia and ReperfusionMitochondrial Function and PathologyNeurological Disorders and Treatments

Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury

Adlam, Victoria J., Harrison, Joanne C., Porteous, Carolyn M., James, Andrew M., Smith, Robin A. J., Murphy, Michael P., Sammut, Ivan A.·2005·The FASEB Journal

Abstract

Mitochondrial oxidative damage contributes to a wide range of pathologies, including cardiovascular disorders and neurodegenerative diseases. Therefore, protecting mitochondria from oxidative damage should be an effective therapeutic strategy. However, conventional antioxidants have limited efficacy due to the difficulty of delivering them to mitochondria in situ. To overcome this problem, we developed mitochondria‐targeted antioxidants, typified by MitoQ, which comprises a lipophilic triphenylphosphonium (TPP) cation covalently attached to a ubiquinol antioxidant. Driven by the large mitochondrial membrane potential, the TPP cation concentrates MitoQ several hundred‐fold within mitochondria, selectively preventing mitochondrial oxidative damage. To test whether MitoQ was active in vivo, we chose a clinically relevant form of mitochondrial oxidative damage: cardiac ischemia‐reperfusion injury. Feeding MitoQ to rats significantly decreased heart dysfunction, cell death, and mitochondrial damage after ischemia‐reperfusion. This protection was due to the antioxidant activity of MitoQ within mitochondria, as an untargeted antioxidant was ineffective and accumulation of the TPP cation alone gave no protection. Therefore, targeting antioxidants to mitochondria in vivo is a promising new therapeutic strategy in the wide range of human diseases such as Parkinson's disease, diabetes, and Friedreich's ataxia where mitochondrial oxidative damage underlies the pathology. Adlam, V. J., Harrison, J. C., Porteous, C. M., James, A. M., Smith, R. A. J., Murphy, M. P., Sammut, I. A. Targeting an antioxidant to mitochondria decreases cardiac ischemia‐reperfusion injury. FASEB J. 19, 1088–1095 (2005)

Integrity signals

Registry

Crossref · 10.1096/fj.05-3718com

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • MitoQ has been tested successfully in human diseases such as Hepatitis C induced liver disease and skin photo damage and in experimental animal models including ischemia-reperfusion, neurodegenerative diseases, diabetes, and alcohol-induced hepatosteatosis.

    “For example, Mitoquinone (MitoQ) has been tested successfully in human diseases such as Hepatitis C induced liver disease and skin photo damage as well as a number of experimental animal models including ischemia-reperfusion, neurodegenerative diseases, diabetes, and alcohol-induced hepatosteatosis [8–14].”
  • When MitoQ is administered to in vivo animal models of pathologies, it reduces both oxidative damage and the pathologies.

    “A number of studies show that, when MitoQ is administered to in vivo animal models of pathologies, it reduces both oxidative damage and the pathologies (Adlam et al., 2005; Lowes et al., 2008; Graham et al., 2009; Supinski et al., 2009; Chacko et al., 2010; Smith and Murphy 2010).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Adlam, V. J., Harrison, J. C., Porteous, C. M., James, A. M., Smith, R. A. J., Murphy, M. P., & Sammut, I. A.
Affiliations
  • University of Otago (NZ)
  • MRC Mitochondrial Biology Unit (GB)
Venue
The FASEB Journal
Publisher
Wiley
Published
2005-07
Volume
19
Issue
9
Pages
1088-1095
ISSN
  • 0892-6638 (ISSN-L)
  • 1530-6860
OpenAlex
W2060179384
Cited by
618
References
39
Citations by year
2026: 10 · 2025: 26 · 2024: 11 · 2023: 17 · 2022: 28 · 2021: 28 · 2020: 38 · 2019: 36 · 2018: 32 · 2017: 25 · 2016: 32 · 2015: 40 · 2014: 45 · 2013: 33 · 2012: 34
FWCI
19.15
Type
journal article
Language
en
Open access
closed
Locations
  • The FASEB Journal (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Cardiac Ischemia and Reperfusion
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
  • Life Sciences › Neuroscience › Neurology › Neurological Disorders and Treatments
Keywords
mitochondria-targeted antioxidants, MitoQ, myocardial ischemia-reperfusion injury, mitochondrial oxidative damage, triphenylphosphonium cation, ubiquinol, mitochondrial membrane potential, cardiac dysfunction, mitochondrial cell death, Parkinson's disease, Friedreich's ataxia, diabetes mellitus
MeSH terms
Animals, Antioxidants, Heart, Male, Mitochondria, Organophosphorus Compounds, Oxygen Consumption, Ubiquinone, Myocardial Reperfusion Injury, Rats, Wistar, Protective Agents, Cytochromes c, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review